Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 149,310 shares of the biopharmaceutical company’s stock after selling 700 shares during the period. New York State Teachers Retirement System owned approximately 0.12% of Catalyst Pharmaceuticals worth $3,621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth $27,000. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $29,000. Farther Finance Advisors LLC grew its position in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares during the period. Sound Income Strategies LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at about $64,000. Finally, GAMMA Investing LLC boosted its position in Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 579 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the transaction, the insider owned 68,873 shares in the company, valued at $1,627,468.99. The trade was a 38.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Preethi Sundaram sold 1,600 shares of the business’s stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider owned 41,081 shares of the company’s stock, valued at $1,085,360.02. This trade represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 247,924 shares of company stock worth $5,879,369. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $20.95 on Tuesday. The company’s 50 day simple moving average is $23.68 and its 200-day simple moving average is $22.90. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of 13.34, a price-to-earnings-growth ratio of 0.87 and a beta of 0.66. Catalyst Pharmaceuticals, Inc. has a 1 year low of $15.19 and a 1 year high of $26.58.

Analyst Ratings Changes

Separately, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. Six analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $32.83.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.